Top 10 Pharma Companies in China in 2021 by R&D Expenditure
BeiGene Ltd, Jiangsu Hengrui Medicine Co Ltd, Zai Lab Ltd, CSPC Pharmaceutical Group Ltd and Innovent Biologics Inc are the 5 top pharma companies in China in 2021 by R&D expenditure. Collectively, the top 10 pharma companies in China reported R&D expenditure of $5,114 million in 2021, the highest R&D expenditure was reported by BeiGene Ltd ($1,459 million), followed by Jiangsu Hengrui Medicine Co Ltd ($891 million) and Zai Lab Ltd ($573 million), while CStone Pharmaceuticals Co Ltd ($202 million) stood the lowest. BeiGene Ltd is one of the leading pharma companies in China by R&D expenditure. The company reported revenues of $1,416 million for the fiscal year ended December 2022 (FY2022), an increase of 20.42% over FY2021. The company is a biotechnology company. It is specialized in the development and commercialization of immuno-oncology medicines to treat cancers. BeiGene also operates through its manufacturing facility which is involved in the production of small molecule and biologics drug candidates in Suzhou, China and employs 8,600 people. Jiangsu Hengrui Medicine Co Ltd is one of the leading pharma companies in China (by R&D expenditure). The company reported revenues of $4,016 million for the fiscal year ended December 2021 (FY2021). The company is a biopharmaceutical company that focuses on the research, development, manufacture, and distribution of novel pharmaceutical products. Its product portfolio includes antitumor drugs, cardiovascular medicines, endocrine medicine, antibiotics, large infusion, and other products and employs 24,491 people. CSPC Pharmaceutical Group Ltd is another leading pharma companies in China (by R&D expenditure). The company reported revenues of $4,598 million for the fiscal year ended December 2022 (FY2022), an increase of 6.41% over FY2021. The company is a pharmaceutical company, which provides innovative, common generic and bulk drugs. It employs 25,147 people.